LIMINATUS PHARMA, INC. Financing Cash Flow
LIMINATUS PHARMA, INC. (LIMN) reported Financing Cash Flow of $5.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- LIMINATUS PHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.08M, a 79.85% decline year-over-year.
- LIMINATUS PHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.59M, a 402.85% increase year-over-year.
- LIMINATUS PHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- LIMINATUS PHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | $5.66M 10-Q · filed 2026-08-14 | $5.66M derived: sum of 3 quarters · filed 2026-08-14 | $5.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.59M S-1 · filed 2026-06-24 | $3.59M derived: sum of 2 quarters · filed 2026-06-24 | $3.59M derived: sum of 3 quarters · filed 2026-06-24 | $13.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $0.00 derived: sum of 2 quarters · filed 2026-06-24 | $10.32M derived: sum of 3 quarters · filed 2026-08-14 | $11.03M S-1 · filed 2026-06-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $10.32M derived: sum of 2 quarters · filed 2026-08-14 | $11.03M 10-Q · filed 2025-11-14 | $11.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $10.32M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | $11.03M 10-Q · filed 2026-08-14 | $11.73M derived: sum of 3 quarters · filed 2026-08-14 | $12.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $713.00K S-1 · filed 2026-06-24 | $1.41M derived: sum of 2 quarters · filed 2026-06-24 | $2.43M derived: sum of 3 quarters · filed 2026-06-24 | |
| 2024-12-31 | $700.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $1.72M derived: sum of 2 quarters · filed 2026-06-24 | $3.92M S-1 · filed 2026-06-24 | |
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.22M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $2.20M 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |